![The NHance® mutation-equipped anti-MET antibody ARGX-111 displays increased tissue penetration and anti-tumor activity in advanced cancer patients The NHance® mutation-equipped anti-MET antibody ARGX-111 displays increased tissue penetration and anti-tumor activity in advanced cancer patients](https://biblio.ugent.be/publication/8730500/file/8730501/thumbnail.png)
The NHance® mutation-equipped anti-MET antibody ARGX-111 displays increased tissue penetration and anti-tumor activity in advanced cancer patients
![Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk | Cancer Cell International | Full Text Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk | Cancer Cell International | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12935-022-02658-z/MediaObjects/12935_2022_2658_Fig1_HTML.png)
Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk | Cancer Cell International | Full Text
![AACR 2023: YH013, a Novel Bispecific EGFR x MET Antibody-Drug Conjugate, Exhibits Potent Anti-Tumor Efficacy - Biocytogen AACR 2023: YH013, a Novel Bispecific EGFR x MET Antibody-Drug Conjugate, Exhibits Potent Anti-Tumor Efficacy - Biocytogen](https://i0.wp.com/biocytogen.com/wp-content/uploads/2023/04/22345-2.png?resize=1024%2C663&ssl=1)
AACR 2023: YH013, a Novel Bispecific EGFR x MET Antibody-Drug Conjugate, Exhibits Potent Anti-Tumor Efficacy - Biocytogen
![Progress and challenge in development of biotherapeutics targeting MET receptor for treatment of advanced cancer - ScienceDirect Progress and challenge in development of biotherapeutics targeting MET receptor for treatment of advanced cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0304419X2030144X-gr3a.jpg)
Progress and challenge in development of biotherapeutics targeting MET receptor for treatment of advanced cancer - ScienceDirect
![Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition | Journal of Nuclear Medicine Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/jnumed/62/3/366/F1.large.jpg)
Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition | Journal of Nuclear Medicine
![Progress and challenge in development of biotherapeutics targeting MET receptor for treatment of advanced cancer - ScienceDirect Progress and challenge in development of biotherapeutics targeting MET receptor for treatment of advanced cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0304419X2030144X-gr3b.jpg)
Progress and challenge in development of biotherapeutics targeting MET receptor for treatment of advanced cancer - ScienceDirect
![Biomedicines | Free Full-Text | Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy Biomedicines | Free Full-Text | Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy](https://www.mdpi.com/biomedicines/biomedicines-02-00359/article_deploy/html/images/biomedicines-02-00359-g001.png)
Biomedicines | Free Full-Text | Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy
![MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM | PNAS MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM | PNAS](https://www.pnas.org/cms/10.1073/pnas.1819085116/asset/06065936-57b2-4390-8eae-93430032d94f/assets/graphic/pnas.1819085116fig01.jpeg)
MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM | PNAS
![Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification | BMC Cancer | Full Text Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-016-2138-z/MediaObjects/12885_2016_2138_Fig1_HTML.gif)
Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification | BMC Cancer | Full Text
![7 Inhibition of MET signaling in cancer therapies. Anti-HGF monoclonal... | Download Scientific Diagram 7 Inhibition of MET signaling in cancer therapies. Anti-HGF monoclonal... | Download Scientific Diagram](https://www.researchgate.net/publication/322197224/figure/fig6/AS:578107776004096@1514843042065/Inhibition-of-MET-signaling-in-cancer-therapies-Anti-HGF-monoclonal-antibodies-interfere.png)